Plasma adiponectin levels are associated with circulating inflammatory cytokines in autoantibody positive first-degree relatives of rheumatoid arthritis patients. by Hughes-Austin, Jan M et al.
UC San Diego
UC San Diego Previously Published Works
Title
Plasma adiponectin levels are associated with circulating inflammatory cytokines in 


















eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Plasma adiponectin levels are associated with
circulating inflammatory cytokines in
autoantibody positive first-degree relatives of
rheumatoid arthritis patients
Jan M. Hughes-Austin1*, Kevin D. Deane2, Jon T. Giles3, Lezlie A. Derber2, Gary O. Zerbe4,
Dana M. Dabelea5, Jeremy Sokolove6, William H. Robinson6, V. Michael Holers2, Jill
M. Norris5
1 Department of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla,
California, United States of America, 2 Department of Rheumatology, School of Medicine, University of
Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America, 3 Division of
Rheumatology, College of Physicians and Surgeons, Columbia University, New York, New York, United
States of America, 4 Department of Biostatistics and Informatics, Colorado School of Public Health,
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America,
5 Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical
Campus, Aurora, Colorado, United States of America, 6 VA Palo Alto Health Care System, Palo Alto,
California and the Division of Immunology and Rheumatology, Stanford University School of Medicine,




Extra-articular manifestations of rheumatoid arthritis (RA), potentially due to systemic
inflammation, include cardiovascular disease and sarcopenic obesity. Adiponectin, an adi-
pose-derived cytokine, has been implicated in inflammatory processes in RA, but little is
known regarding its association with inflammation in a pre-clinical period. Therefore, we
investigated whether adiponectin was associated with inflammatory markers in individuals
at risk for RA, and whether RA-related autoimmunity modifies these associations.
Methods
We analyzed samples from 144 first-degree relatives (FDRs) of RA probands, of whom 23
were positive for anti-cyclic citrullinated peptide antibody and/or 2 rheumatoid factor iso-
types (IgM, IgG or IgA). We called this phenotype the ‘high risk autoantibody profile (HRP)’
as it has been shown in prior work to be >96% specific for future RA. We measured adipo-
nectin, cytokines, and high-sensitivity C-reactive protein (hsCRP). Using linear mixed
effects models, we evaluated interaction between HRP positivity and adiponectin on inflam-
matory markers, adjusting for age, sex, ethnicity, body mass index, pack-years smoking,
and use of cholesterol-lowering medications.
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Results
In everyone, adiponectin concentration was inversely associated with hsCRP and IL-1β in
adjusted models, where a 1% higher adiponectin was associated with a 26% lower hsCRP
(p = 0.04) and a 26% lower IL-1β (p = 0.04). Significant interactions between HRP and adi-
ponectin for associations with GM-CSF, IL-6, and IL-9 were detected in fully adjusted mod-
els (p = 0.0006, p = 0.006, p = 0.01, respectively). In HRP positive FDRs but not HRP
negative FDRs, a 1% higher adiponectin was associated with 97% higher GM-CSF, 73%
higher IL-6, and 54% higher IL-9 concentrations.
Conclusions
Adiponectin associates with inflammatory markers, and these associations differ in individu-
als with a high-risk autoantibody profile compared with those without. The interaction
between adiponectin and autoimmunity warrants further investigation into the potential sys-
temic effects of RA-related autoantibodies and adiponectin on inflammation in the absence
of clinically apparent RA.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized in a major-
ity of cases by the presence of circulating autoantibodies and abnormalities of markers of
inflammation. While the primary manifestation of RA is synovial joint swelling, pain, and
deformity, extra-articular manifestations of RA include cardiovascular disease and sarcopenic
obesity, which are thought to be related to the systemic inflammation in RA. Multiple studies
have shown that RA-autoantibodies, as well as cytokines and chemokines, appear up to 14
years before the onset of RA, suggesting a clear ‘pre-clinical’ period of RA.[1–4] Given this
pre-clinical period of autoimmunity and inflammation, and altered body composition where
muscle mass is lost and adipose tissue is preserved, regardless of changes in body weight, we
hypothesized that adiponectin, a cytokine secreted by adipose tissue, may play a role in this
pre-clinical inflammatory period.
In individuals without autoimmune diseases, adiponectin has been shown to possess anti-
inflammatory, anti-atherogenic, and anti-diabetic properties, as it reduces circulating fatty
acid concentrations and triglyceride levels in muscle and the liver.[5] Adiponectin shares
strong homologies with TNF-α and complement factor C1q, and has been shown to prevent
the transformation of macrophages into foam cells and down-regulate TNF-dependent expres-
sion of several adhesion molecules,[6] thus dampening atherogenic processes. In contrast,
however, higher concentrations of adiponectin have been observed in patients with chronic
autoimmune diseases such as RA and systemic lupus erythematosus (SLE), and have been
directly associated with joint damage in RA.[5, 7, 8] Thus, adiponectin plays a complicated
role in modulating the innate immune system and inflammation—in some states being anti-
inflammatory, but in others perhaps contributing to inflammation and tissue destruction, and
has prompted this investigation.[5, 8]
Previous studies have suggested an active role for adiponectin in inflammatory, matrix-
destructive, and fibrotic processes contributing to joint destruction in RA[5]. Little is known,
however, about adiponectin in the pre-clinical period of RA, and specifically whether autoim-
munity modifies associations between adiponectin and inflammatory markers. Therefore, in
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an effort to identify novel pathways that could be targeted for intervention in the pre-clinical
period of RA in order to avert clinical disease, we investigated whether adiponectin was associ-
ated with inflammatory markers in individuals at risk for RA, and whether autoimmunity
modifies these associations.
Materials and methods
Studies of the Etiology of Rheumatoid Arthritis (SERA) is a multi-center prospective study in the
United States [with sites in New York, Chicago, Omaha (the center of the Rheumatoid Arthritis
Investigational Network), Denver, Seattle, and Los Angeles] that is following first-degree relatives
(FDRs) of probands with RA. SERA was designed to examine the role of environmental and
genetic factors in the development and progression of RA-related autoimmunity, and to explore
pre-clinical immunological changes and pathophysiological processes in the absence of con-
founders such as treatments or secondary complications of active disease. [9, 10] FDRs [parent,
sibling, or offspring] of RA patients were recruited through their probands [identified from aca-
demic centers, Veterans’ hospitals, and rheumatology clinics] or through responses to advertis-
ing. FDRs were eligible to participate if they did not have an RA diagnosis, defined by the 1987
ACR criteria and the 2010 EULAR/ACR criteria, and were18 years old. Institutional Review
Boards at all SERA sites approved this study [Colorado Multiple Institutional Review Board, Uni-
versity of Colorado Anschutz Medical Campus, Aurora, CO, USA; Benaroya Research Institute
Institutional Review Board, Seattle, WA, USA;Cedars-Sinai Medical Center Institutional Review
Board, Los Angeles, CA, USA; Rheumatoid Arthritis Investigational Network [RAIN] at the Uni-
versity of Nebraska Medical Center Institutional Review Board, Omaha, NE, USA; The Feinstein
Institute for Medical Research, Human Research Protection Program Institutional Review
Board, Manhasset, NY, USA; University of Chicago Institutional Review Board, Chicago, IL,
USA], and all participants provided written informed consent.
At research visits, FDRs completed disease and exposure assessment questionnaires, includ-
ing smoking status and medication use, as well as anthropometric measurements (e.g., height
and weight), underwent a standardized interview and 68-count joint examination by a trained
clinician, and had blood drawn. All serum samples were tested for anti-cyclic citrullinated pep-
tide (anti-CCP2) antibodies, rheumatoid factor (RF) by nephelometry, and RF isotypes immu-
noglobulin (Ig) A, G, and M (RF-IgA, RF-IgG, RF-IgM), as described previously.[9] For each
visit, we determined positivity for a high-risk autoantibody profile (HRP), which is defined as
testing positive for anti-CCP2 and/or two RF isotypes, and has been shown to be 96% specific
for future RA.[11]
For this ancillary study, we analyzed 144 FDRs who had complete measures of RA-related
autoantibodies, adiponectin, seven cytokines that have been shown to be associated with RA-
related autoantibodies or adiponectin,[5, 10] and covariates in samples that had been immedi-
ately processed, as delayed sample processing may alter cytokine levels. Of these 144 FDRs, 23
were positive for HRP (HRP(+)), and 121 were negative (HRP(-)). Over a span of six years of
follow up, there were a total of 35 HRP(+) samples and 222 HRP(-) samples, with approxi-
mately 2 ± 1 study visits per FDR.
Total adiponectin (ng/mL) was measured in plasma using the Millipore Milliplex Human
Adiponectin Radioimmunoassay (Millipore, Billerica, Massachusetts, USA). Serum hsCRP was
tested by nephelometric assay (BN II Nephelometer, Dade Behring, Deerfield, Illinois, USA);
and serum cytokines were tested using a bead-based multiplex assay (Beadlyte kit, Upstate,
Charlottesville, Virginia, USA), the Luminex xMAP 100IS platform (Luminex, Austin, Texas,
USA), and BioPlex array reader (Bio-rad Laboratories, Hercules, California) with Luminex fluo-
rescent bead technology, using HeteroblockTM (Omega Biologicals Inc., Bozeman, Montana)
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[12], as described previously.[10, 13] The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series
accessesion number GSE114043 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE114043).
We first evaluated demographic differences by HRP positivity using analysis of covariance
with repeated measures for continuous variables and chi-square tests for proportions. Second,
we examined whether adiponectin and inflammatory marker concentrations differed by HRP
positivity using analysis of covariance with repeated measures. Third, we tested associations
between adiponectin and selected inflammatory markers, and further tested for interactions
between HRP positivity and adiponectin concentration by including an interaction term when
examining the outcome of inflammation. In our analyses with repeated measures, we used lin-
ear mixed-effects models [SAS (version 9.2) PROC MIXED] to account for multiple records
per subject collected over time while adjusting for age, sex, ethnicity, body mass index (BMI)
calculated as weight (kg)/height (m2), smoking pack-years, and current cholesterol-lowering
medication use, as these medications have been shown to be associated with inflammatory
markers. Mixed models provide the best available method to adjust for differing numbers of
visits per subject by estimating the variability between subjects and the variability between
repeated measurements on the same subject separately, and then using functions of these vari-
ance estimates as weights to determine the best estimate of association. In our analysis, both
between subject effects and within subject effects (residuals) were normally distributed. We
selected 7 individual cytokines that had been previously associated with HRP [IL-2, IL-6, IL-9,
GM-CSF, and IFN- γ[10], those shown to be associated with adiponectin [TNF-α, IL-6, IL-1β
and IFN- γ[5], and another well-recognized marker of inflammation [hsCRP]. No adjustments
were made for multiple comparisons, as our a priori hypothesis focused on these specific
inflammatory markers.[14] Adiponectin and the inflammatory markers were natural log-
transformed to satisfy assumptions of distribution normality. Inflammatory markers were
standardized, such that interpretations pertain to a standard deviation (SD) difference of the
marker. These regression coefficients can be interpreted as % change in the inflammatory
marker per 1% increase in adiponectin.
Results
The 144 FDRs evaluated in this analysis were predominantly female (74%), non-Hispanic
white (82%), and never-smokers (65%). At baseline, FDRs were 49 ± 18 years old, BMI was
28 ± 6, and 11% used cholesterol-lowering medications. There were no significant demo-
graphic differences by HRP status. Differences in these descriptive characteristics by HRP phe-
notype are presented in Table 1.
For descriptive purposes, we present median (25th, 75th percentile) levels of adiponectin
and selected inflammatory markers by whether the FDR serum samples for each clinic visit
were HRP(+) versus HRP(-). Adiponectin, hsCRP, IL-1β, IFN-γ, and TNF-α concentrations
did not differ significantly by HRP positivity (Table 2). Concentrations of IL-2, IL6, IL-9, and
GM-CSF, however, were higher in HRP(+) FDRs compared to HRP(-) FDRs (Table 2).
In all subjects, hsCRP and IL-1β were significantly inversely associated with adiponectin
concentration in adjusted models, where a 1% higher adiponectin was associated, on average,
with a 26% lower standardized hsCRP (p = 0.04) and a 26% lower IL-1β (p = 0.04). IL-2, IFN-
γ, and TNF-α were inversely associated with adiponectin concentration in adjusted models as
well, but these associations were not statistically significant. (Table 3).
Significant interactions between HRP and adiponectin for associations with GM-CSF, IL-6,
and IL-9 were detected in fully adjusted models (p = 0.0006, p = 0.006, p = 0.01, respectively),
Adiponectin levels are associated with inflammatory cytokines in pre-clinical rheumatoid arthritis
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where slopes were estimated for associations between adiponectin and inflammatory markers
for HRP(+) and HRP(-) FDRs. These interactions suggest that in HRP(+) FDRs, higher con-
centrations of adiponectin were associated with higher levels of GM-CSF, IL-6, and IL-9, while
no associations were observed in HRP(-) FDRs. (Fig 1). Specifically, in HRP positive FDRs but
not HRP negative FDRs, a 1% higher adiponectin was associated with 97% higher GM-CSF,
73% higher IL-6, and 54% higher IL-9 concentrations. (Fig 1)
Discussion
In FDRs who were positive for a high-risk autoantibody profile specific for future RA, higher
concentrations of adiponectin were significantly associated with higher concentrations of
Table 2. Median (25th, 75th Percentile) levels of adiponectin and inflammatory markers by high-risk autoanti-
body profile (HRP) phenotype in 257 serum/plasma samples from clinic visits of 144 FDRs from the studies of the
Etiology of rheumatoid arthritis (SERA) cohort.
HRP(+) FDRs†
(n = 35 visits by 23 FDRs)
HRP(-) FDRs†
(n = 222 visits by 121 FDRs)
P-value
Adiponectin 12.4 (8.8, 15.7) 11.6 (7.2, 16.1) 0.72
hsCRP 1.2 (0.5, 4.0) 1.8 (0.6, 4.3) 0.3141
IL-1β 1.6 (1.2, 2.0) 1.3 (1.0, 1.7) 0.7517
IL-2 7.7 (0, 20.5) 0 (0, 5.7) 0.002
IL-6 7.1 (5.1, 11.7) 5.3 (4.0, 7.3) 0.0043
IL-9 59.5 (22.3, 894.6) 21.6 (14.4, 58.0) <.0001
GM-CSF 31.8 (20.2, 72.8) 19.3 (12.4, 37.8) 0.0257
IFN-γ 61.3 (38.3, 99.6) 40.9 (28.3, 64.2) 0.133
TNF-α 5.6 (0, 22.7) 4.9 (0, 14.1) 0.2487
These median and 25th and 75th percentile estimates are raw values.
†High Risk Autoantibody Profile (HRP) is defined as positivity for anti-CCP2 and/or two or more RF isotypes, and
has been shown in prior work using pre-clinical RA samples to be >96% specific for future RA.
Differences between HRP(+) versus HRP(-) clinic visits were tested using analysis of covariance with repeated
measures. Subsequent analysis utilizes a natural log-transformed and standardized value for each of these markers.
https://doi.org/10.1371/journal.pone.0199578.t002
Table 1. Population characteristics by high-risk autoantibody profile (HRP) phenotype in 257 serum/plasma sam-
ples from clinic visits of 144 FDRs from the studies of the Etiology of rheumatoid arthritis (SERA) cohort.
HRP(+) FDRs†
(n = 35 visits by 23
FDRs)
HRP(-) FDRs†
(n = 222 visits by 121
FDRs)
P-value
Age, years 47 (16) 49 (17) 0.68
BMI, kg/m2 26 (5) 28 (6) 0.56
Gender, % female 80 72 0.33
Non-Hispanic White, % 86 81 0.51
Current use of cholesterol-lowering
medications, %
11 14 0.64
Ever smoking cigarettes, % 29 35 0.48
†High Risk Autoantibody Profile (HRP) is defined as positivity for anti-CCP2 and/or two or more RF isotypes, and
has been shown in prior work using pre-clinical RA samples to be >96% specific for future RA.
Differences between HRP(+) versus HRP(-) clinic visits were tested using analysis of covariance with repeated
measures.
https://doi.org/10.1371/journal.pone.0199578.t001
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Table 3. Association between adiponectin and markers of inflammation in 257 serum/plasma samples from clinic
visits of 144 FDRs from the studies of the Etiology of rheumatoid arthritis (SERA) cohort.
Markers of Inflammation β (SD) p-value
hsCRP -0.2617 (0.13) 0.0431
IL-1β -0.2644 (0.13) 0.0434
IL-2 -0.1040 (0.14) 0.4539
IFN-γ -0.1395 (0.14) 0.3062
TNF-α -0.2179 (0.13) 0.1053
Adjusted for HRP status, age, sex, ethnicity, BMI, pack-years of smoking, and current use of cholesterol-lowering
medications.
Regression coefficients can be interpreted as % difference in the inflammatory marker per 1% higher adiponectin,
e.g., a 1% higher adiponectin resulted in a 26% lower standardized hsCRP.
https://doi.org/10.1371/journal.pone.0199578.t003
Fig 1. Modification of the association between adiponectin and inflammatory markers (A through H) by HRP status using linear mixed models in the studies of the
Etiology of rheumatoid arthritis. This figure presents the interaction between adiponectin and High-Risk profile autoantibody (HRP) status in 257 serum and plasma
samples from clinic visits of 144 first degree-relatives of RA patients in the Studies of the Etiology of Rheumatoid Arthritis. All analyses were adjusted for age, sex,
ethnicity, BMI, pack-years of smoking, and current use of cholesterol-lowering medications.
https://doi.org/10.1371/journal.pone.0199578.g001
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three pro-inflammatory cytokines, GM-CSF, IL-6, and IL-9. These associations were absent,
however, in FDRs who did not have the high-risk autoantibody profile. Independent of the
HRP status, inflammatory markers hsCRP and IL-1β were inversely associated with adiponec-
tin, which is consistent with the putative anti-inflammatory characteristics of adiponectin.
Taken together, these findings encourage further investigation into associations between adi-
ponectin and inflammatory markers in various environments of autoimmunity.
Several investigators have reported adiponectin’s direct relationship with pro-inflammatory
cytokines in chronic inflammatory diseases such as RA and SLE [5, 15], implying that adipo-
nectin exerts pro-inflammatory effects on effector cells. In particular, in vitro studies have
shown that when stimulated with adiponectin, RA synovial fibroblasts secreted increased con-
centrations of pro-inflammatory cytokines, such as IL-6, as well as various chemokines.[5]
Our findings extend these reports by suggesting that autoimmunity, even in the absence of
clinical RA, modifies adiponectin’s associations with inflammatory markers and potentially its
actions on effector cells. Further, our observation that the high-risk autoantibody profile modi-
fied the association between adiponectin, IL-6, IL-9, and GM-CSF, three markers of systemic
inflammation, and not other inflammatory markers, i.e., hsCRP, IL-1β, IL-2, INF-γ, and TNF-
α, which are indicative of acute inflammation, suggests that the interaction between adiponec-
tin and the high-risk profile may occur systemically. We did not investigate this interaction
between adiponectin and the high-risk autoantibody profile at the level of the joints, and thus
cannot draw conclusions regarding local/acute inflammation based on the current results. Our
results, however, lead us to further pursue future research directions regarding the role of adi-
ponectin in local versus systemic inflammation in the setting of autoimmune disease.
Adiponectin concentration is closely associated with visceral adiposity, which we did not
measure. In addition, we did not measure lean body mass, and were therefore not able to
account for body composition in our analysis. Instead, we adjusted all analyses for BMI, which
may have been an under adjustment for adiposity. It is unlikely that our failure to measure vis-
ceral adiposity resulted in an overestimation of adiponectin’s association with inflammatory
markers, as multiple cell types [e.g. white and brown adipocytes, mucosal cells, liver, skeletal
muscle cells, cardiomyocytes, and salivary gland epithelial cells[16]] produce adiponectin, and
visceral adipose tissue does not account for all circulating adiponectin.
In this study, we did not use a population control group due to the inaccessibility of appro-
priate samples. Instead we utilized an internal control (i.e., autoantibody negative (HRP(-))
FDRs from the cohort), which has many methodological advantages, including the compara-
bility of data acquisition and blood processing, and the lack of selection biases inherent in
external controls. Following FDRs without classifiable RA also allowed us to examine associa-
tions between adiponectin, autoimmunity, and inflammatory markers in a population that is
not receiving treatment for RA, which prevents potential confounding by indication. Another
strength was that we analyzed cytokines as continuous variables. This analysis allowed us to
observe potentially more subtle relationships between these inflammatory markers and adipo-
nectin, which may be more appropriate in individuals without clinically apparent articular dis-
ease. We recognize that our results are not generalizable to individuals of normal BMI, 18.5–
24.9 kg/m2, and to autoantibody-positive individuals who are not first-degree relatives of RA
patients as this particular study investigated only first-degree relatives with an average BMI of
28 ± 6 kg/m2. Future investigations of various BMI categories as well as associations between
adiponectin and cytokines and modification by autoantibody status in non-first-degree rela-
tives would address whether the findings in the present study persist in other populations.
Our adiponectin assay did not distinguish between high- (HMW), middle- (MMW), or low-
(LMW) molecular weight adiponectin. Previous research has demonstrated that LMW adiponec-
tin displays anti-inflammatory properties whereas HMW may display more pro-inflammatory
Adiponectin levels are associated with inflammatory cytokines in pre-clinical rheumatoid arthritis
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effects, and is thought to be a more active form of adiponectin than total adiponectin in the con-
text of metabolic diseases[7]. Therefore, our results may underestimate potential pro-inflamma-
tory relationships between adiponectin and markers of inflammation, which deserves to be
explored in future studies.
Conclusions
In conclusion, in a population without RA, but at increased risk for future RA, adiponectin
associates differentially with inflammatory markers according to autoimmunity status, evi-
denced by its positive associations with pro-inflammatory cytokines solely in HRP positive
FDRs. These findings, in combination with prior studies, suggest that an environment of auto-
immunity may alter the role of adiponectin, and warrants further investigation into the poten-
tial systemic effects of RA-related autoantibodies and adiponectin on inflammation in the
absence of clinically apparent RA.
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